Exhibitors Search
Mthera Pharma Co., Ltd.
Booth no.
H50
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
| |
|
Tel
|
|+82--- |
|
Exhibits
|
| Development of Innovative Disease-Modifying Botanical Drugs for Chronic and Refractory Diseases in the Elderly |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup |
Exhibitor Information
1. R&D of Innovative Botanical Drugs & Natural Product-Derived Products for Treating Chronic and Refractory Diseases in the Elderly
2. Development of Disease-Modifying Therapeutics for Chronic and Refractory Diseases with Unmet Medical Needs Using 'SyMthomics', a Next-Generation Natural Product Drug Discovery Platform Based on AI Virtual Human Systems
2. Development of Disease-Modifying Therapeutics for Chronic and Refractory Diseases with Unmet Medical Needs Using 'SyMthomics', a Next-Generation Natural Product Drug Discovery Platform Based on AI Virtual Human Systems
Exhibit Description
1. Parkinson's disease treatments [botanical drug 'MT101' and core active ingredient NCE candidate 'MT201']: We have completed Phase 1 clinical trials in the U.S. and obtained approval for Phase 2a. We are currently focusing on securing proof of clinical efficacy (PoC) for MT101 in Korea (2026?2027), while simultaneously advancing the development of MT201.
2. Functional food for cognitive enhancement ['MT104']: Clinical trials have been completed. We are securing cash flow through domestic and international commercialization, and our short-term goal is to launch a complex product (Q4 2026), while our long-term goal is to obtain certification for individually approved functional ingredients from the MFDS (Q4 2026).
3. SyMthomics Analysis Services: Maintaining and expanding revenue
2. Functional food for cognitive enhancement ['MT104']: Clinical trials have been completed. We are securing cash flow through domestic and international commercialization, and our short-term goal is to launch a complex product (Q4 2026), while our long-term goal is to obtain certification for individually approved functional ingredients from the MFDS (Q4 2026).
3. SyMthomics Analysis Services: Maintaining and expanding revenue
KYUNGYON EXHIBITION CORP.
